Home › Funds › Paradigm Biocapital Advisors LP › APGE

Paradigm Biocapital Advisors LP position in APGE

APOGEE THERAPEUTICS INC

Paradigm Biocapital Advisors LP reported holding 1,576,385 shares of APGE (APOGEE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$209.2M, representing 3.92% of its reported portfolio and ranking #6 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed APGE holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.58M sh
Reported value held$209.23M
Portfolio Weight3.92%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's APGE position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in APGE in Q1 2024 at 330,000 shares (US$21.9M). The position peaked in Q2 2026 at 1,576,385 shares, worth US$209.2M. Across 10 filings, Paradigm Biocapital Advisors LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,576,385 shares valued at US$209.2M — an increase of 228,142 shares quarter over quarter.. Notable position changes include a 113% increase in Q3 2024, a 83% increase in Q4 2024, a 59% increase in Q3 2025.

Quarter by quarter

QuarterSharesValueChange
Q1 2024 330.00K $21.93M New
Q2 2024 330.00K $12.99M Hold
Q3 2024 701.82K $41.22M Add
Q4 2024 1.28M $58.15M Add
Q1 2025 961.71K $35.93M Reduce
Q2 2025 958.63K $41.63M Hold
Q3 2025 1.52M $60.46M Add
Q4 2025 1.12M $84.78M Reduce
Q1 2026 1.35M $113.48M Add
Q2 2026 1.58M $209.23M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About APGE and 13F data

APGE (APOGEE THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 59 other funds we track also report a position in APGE — the largest reported positions include Venrock Adviser, LLC (US$1.13B), HBK INVESTMENTS L P (US$378.3M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$231.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding APGE

All APGE fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held APGE?

Paradigm Biocapital Advisors LP has disclosed APGE holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Paradigm Biocapital Advisors LP's current position in APGE?

As of Q2 2026, Paradigm Biocapital Advisors LP holds 1.58M shares of APGE (APOGEE THERAPEUTICS INC), valued at $209.23M, representing 3.92% of its reported portfolio and ranking #6.

Has Paradigm Biocapital Advisors LP been buying or selling APGE?

In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP increased its position in APGE. The position peaked in Q2 2026 at 1.58M shares.

Which other funds hold APGE?

Other major institutional holders of APGE include Venrock Adviser, LLC, HBK INVESTMENTS L P, DRIEHAUS CAPITAL MANAGEMENT LLC, among 59 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.